XYN
Bison Capital Acquisition Corp.

73
Loading...
Loading...
Xynomic Pharmaceutical Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:

Frequently Asked Questions

What is Market Cap of Bison Capital Acquisition Corp?
What is the 52-week high for Bison Capital Acquisition Corp?
What is the 52-week low for Bison Capital Acquisition Corp?
What is Bison Capital Acquisition Corp stock price today?
What was Bison Capital Acquisition Corp stock price yesterday?
What is the PE ratio of Bison Capital Acquisition Corp?
What is the Price-to-Book ratio of Bison Capital Acquisition Corp?
What is Bison Capital Acquisition Corp's EBITDA?
What is the 50-day moving average of Bison Capital Acquisition Corp?
How many employess does Bison Capital Acquisition Corp has?

Latest XYN News

View
No XYN news at the moment.

Advertisement. Remove ads.

Advertisement. Remove ads.